The inhibitory effect of recombinant human soluble thrombomodulin on initiation and extension of coagulation. A comparison with other anticoagulonts

Thrombosis and Haemostasis

Volumn 82, Issue 6, 1999, Pages 1687-1693

  Mohri, Mitsunobu ^a   Sugimoto, Emika ^a   Sata, Minako ^a   Asano, Toshio ^a  

^a ASAHI CHEMICAL INDUSTRY CO   (Japan)

Author keywords

Activated protein C; Argatroban; Heparin; Hirudin; Soluble thrombomodulin; Thrombin generation; Thromboelastography

Indexed keywords

ACTIVATED PROTEIN C; ANTICOAGULANT AGENT; ARGATROBAN; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 5A; DALTEPARIN; HEPARIN; HIRUDIN; RECOMBINANT THROMBOMODULIN; THROMBIN;

ANTICOAGULATION; ARTICLE; BLOOD CLOTTING; BLOOD CLOTTING TIME; HUMAN; HUMAN CELL; PRIORITY JOURNAL; THROMBOELASTOGRAPHY;

EID: 0032746547     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1614900     Document Type: Article

References (25)

1. Hemker HC. Thrombin generation, an essential step in haemostasis and thrombosis. In: Haemostasis and Thrombosis 3rd edition. Bloom AL, Forbes CD, Thomas DP, Tuddenham EGD, eds. Edinburgh, UK: Churchill Livingstone 1994; 477-90.
2. James HL. Physiology and biochemistry of prothrombin. In: Haemostasis and Thrombosis 3rd edition. Bloom AL, Forbes CD, Thomas DP, Tuddenham EGD, eds. Edinburgh, UK: Churchill Livingstone 1994; 397-438.
3. Rosing J, Tans G. Coagulation factor V: An old star shines again. Thromb Haemost 1997; 78: 427-33.
4. Rand MD, Lock JB, van't Veer C, Gaffney DP, Mann KG. Blood clotting in minimally altered whole blood. Blood 1996; 88: 3432-45.
5. Thorelli E, Kaufman RJ, Dahlbäck B. Cleavage requirements of factor V in tissue-factor induced thrombin generation. Thromb Haemost 1998; 80: 92-8.
6. Kumar R, Beguin S, Hemker HC. The inflluence of fibrinogen and fibrin on thrombin generation-evidence for feedback activation of the clotting system by clot bound thrombin. Thromb Haemost 1994; 72: 713-21.
7. Francis WC, Markham ER, Barlow HG, Florack MT, Dobrzynski MD, Marder JV. Thrombin activity of fibrin thrombi and soluble plasmic derivatives. J Lab Clin Med 1983; 102: 220-30.
8. Callas D, Fareed J. Comparative pharmacology of site directed antithrombin agents. Implication in drug development. Thromb Haemost 1995; 74: 473-81.
9. Kelly AB, Marzec UM, Krupski W, Bass A, Cadroy Y, Hanson SR, Harker LA. Hirudin interruption of heparin-resistant arterial thrombus formation in baboons. Blood 1991; 77: 1006-12.
10. Lunven C, Gauffeny C, Lecoffre C, O'Brien DP, Roome NO, Berry CN. Inhibition by Argatroban, a specific thrombin inhibitor, of platelet activation by fibrin clot-associated thrombin. Thromb Haemost 1996; 75: 154-60.
11. Lu D, Kalafatis M, Mann KG, Long GL. Comparison of activated protein C/protein S-mediated inactivation of human factor VIII and factor V. Blood 1996; 87: 4708-17.
12. Barrowcliffe TW, Thomas DP. Heparin and low molecular weight heparin. In: Haemostasis and Thrombosis 3rd edition. Bloom AL, Forbes CD, Thomas DP, Tuddenham EGD, eds. Edinburgh, UK: Churchill Livingstone 1994; 1417-38.
13. Gomi K, Zushi M, Honda G, Kawahara S, Matsuzaki O, Yamamoto S, Maruyama I, Suzuki K. Antithrombotic effect of recombinant human thrombo-modulin on thrombin-induced thromboembolism in mice. Blood 1990; 75: 1396-9.
14. Ohishi R, Watanabe N, Aritomi M, Gomi K, Kiyota T, Yamamoto S, Ishida T, Maruyama I. Evidence that the protein C activation pathway amplifies the inhibition of thrombin generation by recombinant human thrombomodulin in plasma. Thromb Haemost 1993; 70: 423-6.
15. Mohri M, Gonda Y, Oka M, Aoki Y, Gomi K. Kiyota T, Sugihara T, Yamamoto S, Ishida T, Maruyama I. The antithrombotic effects of recombinant human soluble thrombomodulin (rhsTM) on tissue factor-induced disseminated intravascular coagulation in crab-eating monkeys (Macaca fascicularis). Blood Coagul Fihrinolysis 1997; 8: 274-83.
16. Mohri M, Sata M, Gomi K, Maruyama Y, Osame M, Maruyama I. Abnormalities in the protein C anticoagulant pathway detected by a novel assay using human thrombomodulin. Lupus 1997; 6: 590-6.
17. Mohri M, Suzuki M, Sugimoto E, Sata M. Yamamoto S, Maruyama I. Effects of recombinant human soluble thrombomodulin (rhs-TM) on clot-induced coagulation in human plasma. Thromb Haemost 1998; 80: 925-9.
18. Harker LA. Marzec UM, Mohri M, Fernandez JA, Kelly AB. Hanson SR, Esmon CT, Griffin JH. Antithrombotic efficacy and safety of recombinant human soluble thrombomodulin in non-human primates: inactivation of thrombin and enhanced generation of activated protein C. Circulation (submitted).
19. Nakashima M, Uematsu T, Umemura K, Maruyama I, Tsuruta K. A novel recombinant human soluble thromhomodulin, ART-123, activates the protein C pathway in healthy male volunteers. J Clin Pharmacol 1998; 38: 540-4.
20. Chandler WL. The thromboelastograph and the thromboelastography technique. Semin Thromb Hemost 1996; 21 (Suppl 4): 1-6.
21. Ichihara K. Comparison of two regression parameters. In: Statistics of bioscience - practical technique and theory. Tokyo, Japan: Nankodo 1990; 218-23.
22. Prasa D, Svendsen L, Sturzebecher J. The ability of thrombin inhibitors to reduce the thrombin activity generated in plasma on extrinsic and intrinsic activation. Thromb Haemost 1997; 77: 498-503.
23. Callas DD, Hoppensteadt D, Fareed J. Comparative studies on the anticoagulant and protease generation inhibitory actions of newly developed site-directed thrombin inhibitory drugs. Efegatran, argatroban. hirulog, and hirudin. Semin Thromh Haemost 1995; 21: 177-83.
24. Nicolaes GAF, Thomassen MCLGD, Tans G, Rosing J, Hemker HC. Effect of activated protein C on thrombin generation and on the thrombin potential in plasma of normal and APC-resistant individuals. Blood Coagul Fibrinolysis 1997; 8: 28-38.
25. Hemker HC, Beguin S. Thrombin generation in plasma: Its assessment via the endogenous thrombin potential. Thromb Haemost 1995; 74: 134-8.